Cargando…
Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism
BACKGROUND: The cytotoxic effects of microtubule-targeting agents (MTAs) are often attributed to targeted effects on mitotic cells. In clinical practice, MTAs are combined with DNA-damaging agents such as ionizing radiation (IR) with the rationale that mitotic cells are highly sensitive to DNA damag...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703169/ https://www.ncbi.nlm.nih.gov/pubmed/29200877 http://dx.doi.org/10.2147/OTT.S143096 |
_version_ | 1783281652409040896 |
---|---|
author | Markowitz, Daniel Ha, Grace Ruggieri, Rosamaria Symons, Marc |
author_facet | Markowitz, Daniel Ha, Grace Ruggieri, Rosamaria Symons, Marc |
author_sort | Markowitz, Daniel |
collection | PubMed |
description | BACKGROUND: The cytotoxic effects of microtubule-targeting agents (MTAs) are often attributed to targeted effects on mitotic cells. In clinical practice, MTAs are combined with DNA-damaging agents such as ionizing radiation (IR) with the rationale that mitotic cells are highly sensitive to DNA damage. In contrast, recent studies suggest that MTAs synergize with IR by interfering with the trafficking of DNA damage response (DDR) proteins during interphase. These studies, however, have yet to demonstrate the functional consequences of interfering with interphase microtubules in the presence of IR. To address this, we combined IR with an established MTA, mebendazole (MBZ), to treat glioma cells exclusively during interphase. MATERIALS AND METHODS: To test whether MTAs can sensitize interphase cells to IR, we treated GL261 and GBM14 glioma cells with MBZ during 3–9 hours post IR (when the mitotic index was 0%). Cell viability was measured using a WST-1 assay, and radiosensitization was quantified using the dose enhancement factor (DEF). The effect of MBZ on the DDR was studied via Western blot analysis of H2AX phosphorylation. To examine the effects of MTAs on intracellular transport of DDR proteins, Nbs1 and Chk2, cytoplasmic and nuclear fractionation studies were conducted following treatment of glioma cells with MBZ. RESULTS: Treatment with MBZ sensitized interphase cells to the effects of IR, with a maximal DEF of 1.34 in GL261 cells and 1.69 in GBM14 cells. Treatment of interphase cells with MBZ led to more sustained γH2AX levels post IR, indicating a delay in the DDR. Exposure of glioma cells to MBZ resulted in a dose-dependent sequestration of Chk2 and Nbs1 in the cytoplasm. CONCLUSION: This study demonstrates that MBZ can sensitize cancer cells to IR independently of the induction of mitotic arrest. In addition, evidence is provided supporting the hypothesis that MTA-induced radiosensitization is mediated by inhibiting DDR protein accumulation into the nucleus. |
format | Online Article Text |
id | pubmed-5703169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-57031692017-11-30 Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism Markowitz, Daniel Ha, Grace Ruggieri, Rosamaria Symons, Marc Onco Targets Ther Original Research BACKGROUND: The cytotoxic effects of microtubule-targeting agents (MTAs) are often attributed to targeted effects on mitotic cells. In clinical practice, MTAs are combined with DNA-damaging agents such as ionizing radiation (IR) with the rationale that mitotic cells are highly sensitive to DNA damage. In contrast, recent studies suggest that MTAs synergize with IR by interfering with the trafficking of DNA damage response (DDR) proteins during interphase. These studies, however, have yet to demonstrate the functional consequences of interfering with interphase microtubules in the presence of IR. To address this, we combined IR with an established MTA, mebendazole (MBZ), to treat glioma cells exclusively during interphase. MATERIALS AND METHODS: To test whether MTAs can sensitize interphase cells to IR, we treated GL261 and GBM14 glioma cells with MBZ during 3–9 hours post IR (when the mitotic index was 0%). Cell viability was measured using a WST-1 assay, and radiosensitization was quantified using the dose enhancement factor (DEF). The effect of MBZ on the DDR was studied via Western blot analysis of H2AX phosphorylation. To examine the effects of MTAs on intracellular transport of DDR proteins, Nbs1 and Chk2, cytoplasmic and nuclear fractionation studies were conducted following treatment of glioma cells with MBZ. RESULTS: Treatment with MBZ sensitized interphase cells to the effects of IR, with a maximal DEF of 1.34 in GL261 cells and 1.69 in GBM14 cells. Treatment of interphase cells with MBZ led to more sustained γH2AX levels post IR, indicating a delay in the DDR. Exposure of glioma cells to MBZ resulted in a dose-dependent sequestration of Chk2 and Nbs1 in the cytoplasm. CONCLUSION: This study demonstrates that MBZ can sensitize cancer cells to IR independently of the induction of mitotic arrest. In addition, evidence is provided supporting the hypothesis that MTA-induced radiosensitization is mediated by inhibiting DDR protein accumulation into the nucleus. Dove Medical Press 2017-11-24 /pmc/articles/PMC5703169/ /pubmed/29200877 http://dx.doi.org/10.2147/OTT.S143096 Text en © 2017 Markowitz et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Markowitz, Daniel Ha, Grace Ruggieri, Rosamaria Symons, Marc Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism |
title | Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism |
title_full | Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism |
title_fullStr | Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism |
title_full_unstemmed | Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism |
title_short | Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism |
title_sort | microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703169/ https://www.ncbi.nlm.nih.gov/pubmed/29200877 http://dx.doi.org/10.2147/OTT.S143096 |
work_keys_str_mv | AT markowitzdaniel microtubuletargetingagentscansensitizecancercellstoionizingradiationbyaninterphasebasedmechanism AT hagrace microtubuletargetingagentscansensitizecancercellstoionizingradiationbyaninterphasebasedmechanism AT ruggierirosamaria microtubuletargetingagentscansensitizecancercellstoionizingradiationbyaninterphasebasedmechanism AT symonsmarc microtubuletargetingagentscansensitizecancercellstoionizingradiationbyaninterphasebasedmechanism |